NASDAQ$ALNY
Alnylam Pharmaceuticals Inc · Q3 2020 earnings
Q3 2020 earnings · · Investor relations
Briefing
Alnylam reported strong Q3 2020 results driven by the performance of ONPATTRO and GIVLAARI, as well as advancements in its late-stage pipeline.
Alnylam Pharmaceuticals reported a strong third quarter in 2020, with significant growth in ONPATTRO and GIVLAARI sales. The company is also expecting potential approval for OXLUMO and LEQVIO, which could further bolster growth. Alnylam is increasing its full-year revenue guidance for ONPATTRO.
- ONPATTRO achieved global net product revenue of $82.5 million, with over 20% quarterly U.S. growth.
- GIVLAARI achieved global net product revenue of $16.7 million.
- Positive CHMP opinions received for OXLUMO and LEQVIO, potentially leading to four approved RNAi therapeutic medicines by year-end 2020.
- Increased 2020 guidance range for ONPATTRO revenue from $280-$300 million to $295-$310 million.
Headline financials
Revenue & EPS history
Alnylam · Revenue · Quarterly
$126M
Revenue by segment
Alnylam · $99.2M total across 2 segments · Q3 2020
- ONPATTRO$82.5M+79.1%83.2%
- GIVLAARI$16.7M—16.8%
Forward guidance
Alnylam updated its full year 2020 financial guidance, increasing the revenue expectations for ONPATTRO.
Tailwinds
- ONPATTRO net product revenues are expected to be between $295 million and $310 million.
- Net revenues from collaborations are expected to be between $100 million and $150 million.
- GAAP R&D and SG&A expenses are expected to be between $1,160 million and $1,255 million.
- Non-GAAP R&D and SG&A expenses are expected to be between $1,000 million and $1,075 million.
- Strategic financing collaboration with Blackstone is expected to enable Alnylam to achieve a self-sustainable financial profile without need for future equity financings.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q3 2020
-1.1%
Avg return
Earnings day
-0.1%
Avg return
5 days after
+3.5%
Avg return
30 days after
48%
31 / 65 earnings
Positive
+15.4%
Q2 2025
Best reaction
-16.9%
Q2 2015
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +4.3% | -0.0% | +0.2% | |
| Q4 2025 | -4.3% | +3.2% | -2.8% | |
| Q3 2025 | -6.7% | -12.1% | -6.3% | |
| Q2 2025 | +15.4% | +23.3% | +31.4% | |
| Q1 2025 | -3.1% | +2.5% | +15.7% | |
| Q4 2024 | -0.4% | -6.0% | -9.1% | |
| Q3 2024 | -2.7% | -5.8% | -10.1% | |
| Q2 2024 | +14.6% | +10.6% | +10.6% | |
| Q1 2024 | +1.6% | +2.9% | -1.0% | |
| Q4 2023 | -10.4% | -8.8% | -9.1% | |
| Q3 2023 | +6.6% | +8.4% | +9.2% | |
| Q2 2023 | -0.8% | -1.2% | +7.6% | |
| Q1 2023 | +6.3% | +4.2% | -2.9% | |
| Q4 2022 | -5.6% | -4.8% | -5.5% | |
| Q3 2022 | +1.7% | +6.0% | +5.8% | |
| Q2 2022 | +0.0% | +0.0% | +48.6% | |
| Q1 2022 | -13.9% | -7.8% | -17.5% | |
| Q4 2021 | -0.4% | +1.3% | +2.4% | |
| Q3 2021 | -16.5% | -12.3% | -1.4% | |
| Q2 2021 | +3.1% | +9.7% | +12.5% | |
| Q1 2021 | -2.0% | -8.3% | -1.1% | |
| Q4 2020 | -3.8% | -6.3% | -13.4% | |
| Q3 2020 | -6.3% | -10.4% | -7.1% | |
| Q2 2020 | -4.6% | -9.2% | -18.4% | |
| Q1 2020 | +0.2% | +0.8% | -9.7% | |
| Q4 2019 | +3.2% | +6.5% | -6.7% | |
| Q3 2019 | +4.3% | +5.5% | +34.2% | |
| Q2 2019 | +12.7% | +13.1% | +16.4% | |
| Q1 2019 | -7.6% | -17.1% | -24.4% | |
| Q4 2018 | -5.0% | +2.5% | +1.8% | |
| Q3 2018 | -15.3% | -21.3% | -13.8% | |
| Q2 2018 | -3.0% | -0.6% | +29.8% | |
| Q1 2018 | +2.6% | +6.8% | +11.8% | |
| Q4 2017 | -5.1% | -2.3% | +9.0% | |
| Q3 2017 | +1.4% | +7.3% | -1.4% | |
| Q2 2017 | -6.8% | -2.2% | -9.5% | |
| Q1 2017 | -4.1% | +1.5% | +31.2% | |
| Q4 2016 | +11.1% | +12.7% | +25.4% | |
| Q3 2016 | -15.1% | -2.0% | +12.4% | |
| Q2 2016 | +9.9% | +7.1% | -3.1% | |
| Q1 2016 | -9.3% | — | — | |
| Q4 2015 | +4.5% | — | — | |
| Q3 2015 | +5.6% | — | — | |
| Q2 2015 | -16.9% | — | — | |
| Q1 2015 | +6.7% | — | — | |
| Q4 2014 | +2.3% | — | — | |
| Q3 2014 | +3.2% | — | — | |
| Q2 2014 | +1.5% | — | — | |
| Q1 2014 | +5.3% | — | — | |
| Q4 2013 | -2.1% | — | — | |
| Q3 2013 | -11.2% | — | — | |
| Q2 2013 | +3.7% | — | — | |
| Q1 2013 | +3.5% | — | — | |
| Q4 2012 | -0.7% | — | — | |
| Q3 2012 | +0.7% | — | — | |
| Q2 2012 | -1.5% | — | — | |
| Q1 2012 | -9.0% | — | — | |
| Q4 2011 | -9.6% | — | — | |
| Q3 2011 | +1.5% | — | — | |
| Q2 2011 | -14.9% | — | — | |
| Q1 2011 | +2.3% | — | — | |
| Q4 2010 | +13.2% | — | — | |
| Q3 2010 | +2.4% | — | — | |
| Q2 2010 | -0.9% | — | — | |
| Q1 2010 | -5.3% | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro